This idea is strengthened by recent findings that lenalidomide, an oral immunomodulatory drug that has stimulatory effects on NK-cells and T-cells and downregulates the MYC protein via cereblon modulation [54,55], is beneficial in addition to R-CHOP in patients with MYC-rearranged DLBCL [56]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.